AVO maintains operational and commercial momentum

Advanced Oncotherapy CEO Nicolas Serandour

Advanced Oncotherapy (AVO) said it had made ‘significant progress’ in its corporate objectives and maintained commercial momentum over the last 12 months despite the Covid-19 pandemic….

You must be a HM Subscriber to view this content.

Subscribe Now »